MindMed (MNMD stock) announces first dosing of LSD drug in phase 2b trial

MindMed (MNMD) announced early Thursday that it had begun its phase 2b trial for its Generalized Anxiety Disorder (GAD) drug MM-120. Shares of the psy

Related Keywords

Robert Barrow ,Jake Freeman ,Scott Freeman ,University Hospital Basel ,Food Drug Administration ,Generalized Anxiety Disorder ,Bed Bath ,Drug Administration ,Healthcare ,Technical Analysis ,Quities ,